Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2025

Efficacy and Safety of PD-1 Inhibitors Combined with Transarterial Chemoembolization (TACE) and targeted Therapy in Advanced Primary Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChang LiuQHQihui HuZCZhiyu Chen

Discussion

Loading...

Member takes

Overview

Retrospective analysis found improved objective response and progression-free survival in liver cancer patients with triple therapy, suggesting enhanced treatment options.

Key Points

  • Triple therapy with pd-1 inhibitors, tace, and targeted therapy demonstrated a 56.3% objective response rate compared to 19.4% in the control group.
  • The study included 68 patients with advanced primary hepatocellular carcinoma from several hospitals in China.
  • Adverse reactions were mostly mild, with no severe events reported, indicating a favorable safety profile.
  • This combination strategy offers significant improvements in efficacy, emphasizing potential for better patient outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cc08dhttps://doi.org/10.21203/rs.3.rs-6998613/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma2025
  2. 2TACE Combined with PD-L1 Inhibitors Effectively Mitigates TACE Resistance in Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Study2025
  3. 3Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis2025 · 7 citations
  4. 4Preoperative TACE with PD-1 inhibitors and TKIs in beyond “up-to-seven” hepatocellular carcinoma: a propensity score matched analysis2025 · 1 citations
  5. 5Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China2025